Thomas G Stewart
Overview
Explore the profile of Thomas G Stewart including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
63
Citations
756
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rothman R, Stewart T, Mourad A, Boulware D, McCarthy M, Thicklin F, et al.
JAMA Netw Open
. 2024 Oct;
7(10):e2439332.
PMID: 39422912
Importance: The effect of montelukast in reducing symptom duration among outpatients with mild to moderate COVID-19 is uncertain. Objective: To assess the effectiveness of montelukast compared with placebo in treating...
2.
Rohde M, French B, Stewart T, Harrell Jr F
Stat Med
. 2024 Jun;
43(18):3539-3561.
PMID: 38853380
Ordinal longitudinal outcomes are becoming common in clinical research, particularly in the context of COVID-19 clinical trials. These outcomes are information-rich and can increase the statistical efficiency of a study...
3.
Rothman R, Stewart T, Mourad A, Boulware D, McCarthy M, Thicklin F, et al.
medRxiv
. 2024 May;
PMID: 38798524
Importance: The effect of montelukast in reducing symptom duration among outpatients with mild to moderate coronavirus disease 2019 (COVID-19) is uncertain. Objective: To assess the effectiveness of montelukast compared with...
4.
McCarthy M, Lindsell C, Rajasingham R, Stewart T, Boulware D, Naggie S
J Clin Transl Sci
. 2024 Feb;
8(1):e19.
PMID: 38384913
No abstract available.
5.
Stewart T, Rebolledo P, Mourad A, Lindsell C, Boulware D, McCarthy M, et al.
JAMA
. 2023 Nov;
330(24):2354-2363.
PMID: 37976072
Importance: The effect of higher-dose fluvoxamine in reducing symptom duration among outpatients with mild to moderate COVID-19 remains uncertain. Objective: To assess the effectiveness of fluvoxamine, 100 mg twice daily,...
6.
Boulware D, Lindsell C, Stewart T, Hernandez A, Collins S, McCarthy M, et al.
N Engl J Med
. 2023 Sep;
389(12):1085-1095.
PMID: 37733308
Background: The effectiveness of inhaled glucocorticoids in shortening the time to symptom resolution or preventing hospitalization or death among outpatients with mild-to-moderate coronavirus disease 2019 (Covid-19) is unclear. Methods: We...
7.
High tissue-sodium associates with systemic inflammation and insulin resistance in obese individuals
Ertuglu L, Sahinoz M, Alsouqi A, Deger S, Guide A, Stewart T, et al.
Nutr Metab Cardiovasc Dis
. 2023 May;
33(7):1398-1406.
PMID: 37156670
Background And Aims: High sodium intake is associated with obesity and insulin resistance, and high extracellular sodium content may induce systemic inflammation, leading to cardiovascular disease. In this study, we...
8.
Naggie S, Boulware D, Lindsell C, Stewart T, Slandzicki A, Lim S, et al.
JAMA
. 2023 Feb;
329(11):888-897.
PMID: 36807465
Importance: It is unknown whether ivermectin, with a maximum targeted dose of 600 μg/kg, shortens symptom duration or prevents hospitalization among outpatients with mild to moderate COVID-19. Objective: To evaluate...
9.
Bell J, Cook S, Edwards T, Rice T, Self W, Wheeler A, et al.
J Clin Transl Sci
. 2023 Feb;
7(1):e9.
PMID: 36755543
Racially and ethnically minoritized populations have been historically excluded and underrepresented in research. This paper will describe best practices in multicultural and multilingual awareness-raising strategies used by the Recruitment Innovation...
10.
McCarthy M, Naggie S, Boulware D, Lindsell C, Stewart T, Felker G, et al.
JAMA
. 2023 Jan;
329(4):296-305.
PMID: 36633838
Importance: The effectiveness of fluvoxamine to shorten symptom duration or prevent hospitalization among outpatients with mild to moderate symptomatic COVID-19 is unclear. Objective: To evaluate the efficacy of low-dose fluvoxamine...